Co-Authors
This is a "connection" page, showing publications co-authored by HELEN PIWNICA-WORMS and STACY MOULDER.
Connection Strength
1.708
-
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-na?ve and longitudinal samples throughout neoadjuvant chemotherapy. bioRxiv. 2024 Nov 28.
Score: 0.248
-
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer. NPJ Breast Cancer. 2024 May 27; 10(1):37.
Score: 0.240
-
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2.
Score: 0.218
-
Pharmacologic profiling of patient-derived xenograft models of primary treatment-na?ve triple-negative breast cancer. Sci Rep. 2020 10 21; 10(1):17899.
Score: 0.187
-
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019 04 17; 11(488).
Score: 0.168
-
High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun. 2018 11 29; 9(1):5079.
Score: 0.164
-
A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ Breast Cancer. 2018; 4:9.
Score: 0.157
-
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
Score: 0.055
-
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment na?ve gBRCA+ breast cancers. NPJ Breast Cancer. 2022 May 10; 8(1):64.
Score: 0.052
-
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021 09 10; 12(1):5389.
Score: 0.050
-
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020 11 04; 22(1):121.
Score: 0.047
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.043
-
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7.
Score: 0.040
-
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017; 3:49.
Score: 0.038